Regulus Therapeutics Inc (NASDAQ:RGLS)

Data as of 11:47am ET
 +0.33 / +1.87%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Other

Company Description

Regulus Therapeutics, Inc. discovers and develops pharmaceutical products. It is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a broad range of diseases. The company intends to focus its proprietary efforts on developing microRNA therapeutics for oncology indications and orphan diseases and is currently advancing several programs toward clinical development in oncology, fibrosis and metabolic diseases. It is developing RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, a life-threatening kidney disease driven by genetic mutations with no approved therapy, and RG-101, a GalNAc-conjugated anti-miR targeting microRNA-122 for the treatment of chronic hepatitis C virus infection. Regulus Therapeutics was founded in September 2007 and is headquartered in San Diego, CA.

Contact Information

Regulus Therapeutics, Inc.
3545 John Hopkins Court
San Diego California 92121-1121
P:(858) 202-6300
Investor Relations:
(858) 202-6321



Individual stakeholders43.45%
Mutual fund holders27.82%
Other institutional12.64%

Top Executives

Kleanthis G. XanthopoulosPresident, CEO, CFO, Director & CAO
Neil W. GibsonChief Scientific Officer
Paul C. GrintChief Medical Officer
Daniel R. ChevallardVice President-Finance & Accounting
Amy ConradDirector-Investor Relations & Communications

Most stock quote data provided by BATS. Market indices are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer.

Morningstar: © 2015 Morningstar, Inc. All Rights Reserved.

Factset: FactSet Research Systems Inc. 2015. All rights reserved.

Chicago Mercantile Association: Certain market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved.

Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. Standard & Poor's and S&P are registered trademarks of Standard & Poor’s Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All content of the Dow Jones branded indices © S&P Dow Jones Indices LLC 2015 and/or its affiliates.